ABSTRACT
Every health economic evaluation must give rise to clear conclusions. Among other things, this means that it is reported for what indications, what patients, and in comparison with what alternatives a certain cost-effectiveness value was found. It is not acceptable to state in general terms that a medicine or a technology is cost-effective. This conclusion must always be accompanied by the indication, the target population, and the strategy with which comparisons were made. The conclusion must also indicate to what extent the results are robust (on the basis of the sensitivity analysis) and which variables should be subjected to further examination in the future.
